Table 2.
Percentage of health facilities with the required resources for implementation of the new national malaria treatment protocol
|
Resource |
Health centre |
Aid post |
Overall |
|||
|---|---|---|---|---|---|---|
| % | (95% CI) | % | (95% CI) | % | (95% CI) | |
|
Diagnostic Test |
|
|
|
|
|
|
| RDT |
90.2 |
(76.9, 97.3) |
21.3 |
(10.7, 35.7) |
53.4 |
(42.5, 64.1) |
| Microscopya, |
7.3 |
(1.5, 19.9) |
2.1 |
(<0.1, 11.3) |
4.6 |
(1.3, 11.2) |
| RDT or microscopy |
90.2 |
(76.9, 97.3) |
21.3 |
(10.7, 35.7) |
53.4 |
(42.5, 64.1) |
|
Recommended medication – first- and second-line treatment
b
| ||||||
| ALc, all categories |
87.8 |
(73.8, 95.9) |
19.2 |
(9.1, 33.3) |
51.1 |
(40.2, 61.9) |
| AL, 5–15 kg |
95.1 |
(83.5, 99.4) |
21.3 |
(10.7, 35.7) |
55.7 |
(44.7, 56.3) |
| AL, 15-25 kg |
92.7 |
(80.1, 98.5) |
23.4 |
(12.3, 38.0) |
55.7 |
(44.7, 56.3) |
| AL, 25–35 kg |
92.7 |
(80.1, 98.5) |
19.2 |
(9.1, 33.3) |
53.4 |
(42.5, 64.1) |
| AL, 35+ kg |
92.7 |
(80.1, 98.5) |
23.4 |
(12.3, 38.0) |
55.7 |
(44.7, 56.3) |
| AL + PQd |
68.3 |
(51.9, 81.9) |
14.9 |
(6.2, 28.3) |
39.8 |
(29.5, 50.1) |
| DPe |
4.9 |
(<0.1, 16.5) |
0 |
- |
2.3 |
(<0.1, 8.0) |
| AI + ALf |
70.7 |
(54.5, 83.9) |
8.5 |
(2.4, 20.4) |
37.5 |
(27.4, 48.5) |
| AI + AL + PQg |
61.0 |
(44.5, 75.8) |
8.5 |
(2.4, 20.4) |
33.0 |
(23.3, 43.8) |
| QI + QT + DXh |
65.9 |
(49.4, 79.9) |
29.8 |
(17.3, 44.9) |
46.6 |
(35.9, 57.5) |
|
Selected ‘other’ anti-malarial medication | ||||||
| SP |
97.6 |
(87.1, 99.9) |
87.2 |
(74.3, 95.2) |
92.1 |
(84.3, 96.7) |
| CQ |
92.7 |
(80.1, 98.5) |
85.1 |
(71.7, 93.8) |
88.6 |
(80.1, 94.4) |
| AQ |
92.7 |
(80.1, 98.5) |
87.2 |
(74.3, 95.2) |
89.8 |
(81.5, 95.2) |
| Artemether tablets | 68.3 | (51.9, 81.9) | 42.6 | (28.3, 57.8) | 54.6 | (43.6, 65.2) |
aMicroscopy was defined as the presence of a functional microscope, all essential supplies (Giemsa stain, slides and, in the case of electric microscopes, power) and a trained microscopist in employment.
bThe quantity of each medication was not accounted for in this analysis; rather, the data represent the percentage of health facilities that had at least one vial or container (inclusive of a single, opened container) of the respective anti-malarial in stock.
cFirst-line treatment for uncomplicated P. falciparum infection.
dFirst-lline treatment for uncomplicated P. vivax infection.
eSecond-line treatment for uncomplicated malaria infection.
fFirst-line treatment for severe P. falciparum infection.
gFirst-line treatment for severe P. vivax infection.
hSecond-line treatment for severe malaria infection.
AL = artemether-lumefantrine, PQ = primaquine, DP = dihydroartemisinin-piperaquine, AI = artemether or artesunate injection, QI = quinine injection, QT = quinine tablets, DX = doxycycline, SP = sulphadoxine-pyrimethamine, CQ = chloroquine, AQ = amodiaquine.